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Abstract
Background: Culture of Mycobacterium tuberculosis currently represents the closest ‘‘gold standard’’ for diagnosis of
tuberculosis (TB), but operational data are scant on the impact and cost-effectiveness of TB culture for human
immunodeficiency (HIV-) infected individuals in resource-limited settings.
Methodology/Principal Findings: We recorded costs, laboratory results, and dates of initiating TB therapy in a centralized TB
culture program for HIV-infected patients in Rio de Janeiro, Brazil, constructing a decision-analysis model to estimate the
incremental cost-effectiveness of TB culture from the perspective of a public-sector TB control program. Of 217 TB suspects
presenting between January 2006 and March 2008, 33 (15%) had culture-confirmed active tuberculosis; 23 (70%) were smear-
negative. Among smear-negative, culture-positive patients, 6 (26%) began TB therapy before culture results were available, 11
(48%) began TB therapy after culture result availability, and 6 (26%) did not begin TB therapy within 180 days of presentation.
The cost per negative culture was US$17.52 (solid media)–$23.50 (liquid media). Per 1,000 TB suspects and compared with
smear alone, TB culture with solid media would avert an estimated eight TB deaths (95% simulation interval [SI]: 4, 15) and 37
disability-adjusted life years (DALYs) (95% SI: 13, 76), at a cost of $36 (95% SI: $25, $50) per TB suspect or $962 (95% SI: $469,
$2642) per DALY averted. Replacing solid media with automated liquid culture would avert one further death (95% SI: 21, 4)
and eight DALYs (95% SI: 24, 23) at $2751 per DALY (95% SI: $680, dominated). The cost-effectiveness of TB culture was more
sensitive to characteristics of the existing TB diagnostic system than to the accuracy or cost of TB culture.
Conclusions/Significance: TB culture is potentially effective and cost-effective for HIV-positive patients in resource-
constrained settings. Reliable transmission of culture results to patients and integration with existing systems are essential.
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Introduction
Human immunodeficiency virus (HIV) infection dramatically
increases the incidence, severity, and mortality risk of active
tuberculosis (TB) [1]. Unfortunately, HIV also complicates TB
diagnosis. In HIV-infected patients, sputum smear microscopy has
an estimated sensitivity of 35% for active TB [2], and smear-
negative TB is associated with worse clinical outcomes than smear-
positive disease [3,4]. Improved diagnosis of TB in HIV-infected
individuals is recognized as an increasingly urgent priority [5].
While many promising novel TB diagnostics are being developed
[6,7], expanded use of TB culture may have an immediate impact on
TB rates in high-burden countries [8,9]. Culture of Mycobacterium
tuberculosis from clinical specimens currently represents the closest
‘‘gold standard’’ for diagnosis of TB [5]. Despite routine use
throughout the developed world, TB culture remains unavailable in
mosthigh-burdencountries,largelyduetoexpenseandinfrastructure
requirements [10,11]. However, a number of high-burden countries
have now developed laboratory capacity to perform TB culture [12],
and automated systems using liquid media are now available that
may reducethe corresponding human resourcerequirement [13]. To
date, operational data are scant on the impact and cost-effectiveness
of programs performing TB culture for HIV-infected individuals in
resource-limited settings[14,15]. Thus,we evaluated costs, laboratory
results, clinical events (e.g., initiation and completion of TB therapy),
and projected clinical outcomes (e.g., TB mortality) at a centralized
referrallaboratoryofferingculturetoHIV-positiveTBsuspectsacross
29 clinics in Rio de Janeiro, Brazil.
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Objectives
Our objectives were to estimate the impact and cost-effectiveness
of mycobacterial culture for the diagnosis of TB in an urban setting
in Latin America. Our primary outcome was the incremental cost-
effectiveness ratio (ICER), expressed as the cost, in 2006 US dollars,
per disability-adjusted life year (DALY) averted.
Study Design and Participants
We performed a field evaluation of centralized TB culture in the
context of the TB/HIV in Rio (THRio) study, details of which
have been published elsewhere [16]. Briefly, THRio is a cluster-
randomized trial of tuberculin skin testing and isoniazid preventive
therapy for HIV-positive patients, taking place at 29 municipal
health clinics and hospitals in Rio de Janeiro, Brazil. In a
‘‘stepped-wedge’’ design, two clinics were randomized to begin
receiving the study intervention on a bimonthly basis, until all
clinics were phased-in over a period of 30 months. Thus, data on
the first two clinics were available for the entire study period, and
on the last two clinics only for the final month. Data on all enrolled
patients, including dates of TB diagnoses and outcomes of TB
treatment, were abstracted from medical charts and clinic records
on a semi-annual basis.
As clinics were phased-in to receive the THRio study
intervention, they also became eligible to order TB culture
through a centralized mycobacteriology laboratory. At this time,
physicians and nurses were given standardized requisition forms
and briefly trained to order TB culture on all HIV-positive
pulmonary TB suspects (i.e., excluding HIV-negative patients,
asymptomatic patients, and patients already being treated for
active TB), recommending collection of two specimens per patient.
Specimens were then collected throughout the week and
refrigerated (before processing) until delivery to the laboratory
on a weekly basis by secure motorized transport. Results from the
laboratory were reported back to clinics on a weekly basis; thus,
positive culture results were reported before the results of species
identification (which were reported on all culture-positive
specimens). In addition, a study nurse coordinated lab-clinic
communication (including immediate reporting of positive smear
results in order to insure that smear results would be available if
patients were told to return in one week) and performed ongoing
training, data management, and quality assurance.
The present analysis includes all patients who met the following
criteria: (a) presentation to a THRio intervention clinic with
symptoms and/or signs compatible with pulmonary TB between
January 1, 2006, and March 15, 2008; (b) confirmed HIV-positive;
(c) not diagnosed with TB in the period between 15 and 365 days
before presentation; (d) at least one acceptable specimen for TB
culture submitted; and (e) data on culture result and clinical TB
diagnosis available for 180 days beyond specimen submission.
Laboratory data were analyzed and reported by diagnostic
attempt, defined as a series of TB culture specimens submitted
within any continuous 15-day period.
Laboratory Procedures
All specimens were decontaminated using a commercialized N-
acetyl-L-cysteine/NaOH preparation (Mycoprep
TM, BD Corpora-
tion, Franklin Lakes, NJ). Ziehl-Neelsen sputum smear microscopy
was performed according to standard procedures [17]. Smears were
prepared both before and after centrifugation [18], with a positive
result taken as detection of 10 acid-fast bacilli (AFB) per 100 high-
power fields on either examination. According to the standard
practice of the Brazilian reference laboratory, TB culture on solid
media was performed by inoculating 100 mL of decontaminated
material into each of five Lowenstein-Jensen (L-J) slants: three with
no added inhibitors, one with 500 mg/L p-nitrobenzoic acid
[PNB], and one with 5 mg/L thiophen-2-carboxylic acid hydrazide
[TCH]. Specimens were incubated at 37uC and examined on a
weekly basis for eight weeks. All results were verified by Ziehl-
Neelsen microscopy, and all slants showing growth of AFB (one per
patient specimen) were sub-cultured and subjected to species
identification with standard biochemical tests [17].
Culture in liquid media was performed using the Mycobacteria
Growth Indicator Tube [MGIT
TM] 960 automated system (BD
Corporation, Franklin Lakes, NJ) using 1 culture tube per
specimen. Tubes marked as having growth by the automated
system were manually assessed for AFB using Ziehl-Neelsen
microscopy; all tubes positive for AFB were sub-cultured on L-J
media and species identification was performed as above. For
specimens showing growth of other organisms in liquid culture,
centrifuged pellets from the original decontaminated sputa (which
were frozen at 220uC) were subjected to repeat decontamination
and re-inoculation into fresh tubes, from which the final culture
result was then obtained.
A patient’s culture result was considered contaminated only if all
slants or tubes from all cultures from all specimens during a
diagnostic attempt revealed growth of organisms other than AFB.
Otherwise, a positive result was taken as a single colony on solid
media, or a single positive tube using liquid media, that revealed
AFB on Ziehl-Neelsen microscopy. The absence of colonies (L-J)
or fluorescence (MGIT) on all non-contaminated specimens
qualified as a negative result. All results were entered into a
computerized laboratory database and linked with patient records
from the THRio study.
Cost-Effectiveness Analysis
In this study, an expanded TB culture program was initiated in a
standing bacteriology laboratory with sufficient existing infrastruc-
ture (e.g., biosafety laboratory space, autoclaves), but without the
resources (e.g., staff, equipment, supplies) for program initiation or
maintenance. Reasoning that existing laboratory infrastructure may
be a pre-condition for the cost-effective establishment of TB culture
programs in many developing countries, we adoptedthe perspective
of a public-sector TB control program with such infrastructure
available, deciding whether to fund expanded TB culture. The
reference scenario, therefore, is the situation in which the central
laboratory does not perform TB culture despite capacity to do so;
less than 5% of Brazilian laboratories that perform sputum smear
microscopy currently perform TB culture [12]. In this reference
scenario, we assume that all TB suspects have sputum smears
performed at a local laboratory, at the same cost as if performed in
the central laboratory.
Using decision analysis, we estimated the incremental cost-
effectiveness of sputum smear microscopy plus expanded TB
culture using (a) L-J solid media and (b) liquid media with MGIT,
against the reference scenario of sputum smear microscopy alone.
Secondary outcomes included incremental TB diagnoses made,
incremental deaths averted, and incremental secondary infections
averted. We performed our analysis using a hypothetical cohort of
HIV-positive patients presenting to municipal health clinics with
symptoms of pulmonary TB (e.g., cough of three weeks’ duration).
Among patients with active TB, we assumed that TB culture
offers no benefit among sputum-smear positive patients, and that a
proportion of patients (as estimated by the World Health
Organization, WHO [19]) are diagnosed with smear-negative
TB on the basis of tools other than culture (e.g., chest X-ray,
clinical judgment). Thus, TB culture offers benefit only to those
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all other available clinical tools. The cost of false-positive diagnosis
was incorporated as the cost of TB treatment, plus a correspond-
ing decrement in quality of life while on TB therapy. Patients with
undiagnosed TB were assumed to experience a monthly mortality
risk commensurate with the estimated case-fatality rate for
untreated TB in HIV-positive Brazilian adults [19], assuming a
constant proportion of deaths in each of 12 months. Such patients
were also assumed to generate secondary TB infections at a
defined monthly rate. Those secondary infections progressing
rapidly to active TB were assumed to result in immediate loss of
quality-adjusted life; latent infections and ‘‘tertiary’’ infections
resulting from secondary cases were ignored. A Markov process
was used to model the assumption that patients with undiagnosed
TB would present to the same clinic for re-diagnosis, at a rate
determined by the time interval between repeat specimen
submissions, until diagnosis or death. The time horizon was taken
as the life of the cohort, with future costs and DALYs discounted at
3% per year (i.e., costs and DALYs in future years are valued at
97% of their value in the preceding year).
Where possible, model parameter estimates were based on
direct study data; otherwise, parameter estimates were obtained
from the literature. Costs were obtained directly from laboratory
budget records and staff interviews using an ‘‘ingredients’’
approach; only those incremental costs accruing to the municipal
tuberculosis program for initiation and maintenance of TB culture
were included. Certain items (e.g., freezers, incubators, laboratory
chemicals) were not directly purchased by the municipal
tuberculosis program; their costs were estimated according to
Brazilian market values. Costs of capital items were annualized
over their useful lives. Useful life was estimated according to
WHO-CHOosing Interventions that are Cost-Effective
(CHOICE) published values where available [20]; otherwise,
laboratory equipment items (i.e., MGIT reader, centrifuge) were
assumed to have a useful life of 10 years, while supplies (e.g.,
pipettes, reusable glassware) were assumed to last 5 years.
Estimated test characteristics were based on actual field perfor-
mance, using any positive culture for M. tuberculosis or initiation of
TB treatment as the definition of a TB case. Outcomes and
effectiveness were estimated by linkage of patient lab records to
medical charts in the THRio database.
Sensitivity and Uncertainty Analysis
We performed one-way sensitivity analyses on all model
parameters, evaluating the impact on incremental cost-effective-
ness (comparing TB culture with solid media to the baseline
scenario) of a 625% change in parameter value. To assess the
impact of simultaneous changes in all model parameters, we also
performed multivariate uncertanty analysis, varying all parameter
estimates over beta distributions (for variables bounded between 0
and 1) or gamma distributions (for variables bounded between 0
and infinity), with means set to expected parameter values and
standard deviations set to 12.5% of expected parameter values.
The results of 10,000 simulations are presented as 95% simulation
intervals, which correspond to the 2.5
th and 97.5
th percentile of
simulated results.
Ethics
This study operated under a waiver of informed consent, as it
involved secondary collection of de-identified data after imple-
menting the standard of care for TB diagnosis, as recommended
by the City of Rio de Janeiro. This study was approved by the
institutional review boards of the Johns Hopkins Medical
Institutions and the City of Rio de Janeiro.
Results
Laboratory Outcomes and Treatment Initiation
A total of 217 eligible patients submitted 398 TB culture
specimens during 235 diagnostic attempts, a mean of 1.69
specimens per attempt. Of these, 33 patients (15%) had M.
tuberculosis isolated from at least one culture; 10 (30%) were smear-
positive on initial evaluation. An additional 17 patients (7%) had
cultures positive for non-tuberculous mycobacteria (NTM) (11 M.
fortuitum,4M. avium,1M. kansasii ¸ 1 M. flavescens), and 19 patients
(9%) were treated for TB without a positive culture (Figure 1).
To minimize costs, we adopted different processing algorithms
for solid versus liquid culture media. According to laboratory
routine, five solid L-J slants were prepared from each specimen,
and a new specimen was requested if all five slants showed
contamination. By contrast, only a single MGIT tube was initially
prepared for each specimen, but contaminated specimens were re-
processed for repeat culture. Ignoring re-processing, sensitivity for
culture-confirmed, smear-negative TB was identical (17/
23=74%) for solid media (5 slants) versus MGIT (1 tube), but
MGIT was faster (mean time to culture growth 20.0 versus 31.9
days, p=0.0001) and more likely to detect non-tuberculous
mycobacteria (NTM) (14/17=82% versus 8/17=47%,
p=0.03). Of MGIT specimens, 14% were contaminated, versus
9% for five L-J slants (p=0.22). Re-processing MGIT specimens
yielded two additional TB diagnoses; updated MGIT sensitivity
was thus 83% (19/23). The sensitivity estimates used for the cost-
effectiveness model are somewhat lower than these figures, since
the cost-effectiveness model assumes that some smear-negative TB
cases are also culture-negative.
Treatment for TB was initiated in 49 patients: 8/10 (80%) with
smear-positive TB, 17/23 (74%) with culture-confirmed smear-
negative TB, 8/17 (47%) with cultures positive for NTM, and 16/
167 (10%) with negative smears and cultures (Figure 1). Among 17
patients with culture-confirmed smear-negative TB who were
treated, six (35%) began treatment before culture results became
available. Among eight treated patients with cultures positive for
NTM, three (37.5%) began TB treatment before culture results
were reported. Thus, 5/14 (36%) untreated NTM-positive patients
were placed on TB therapy after receiving a positive culture result;
these patients completed 81% (mean) of a full treatment course of
a full treatment course before stopping therapy for TB. Although
species identification results were reported promptly on all
patients, 50% of patients with cultures positive for NTM
completed a full course of TB therapy and were registered as
TB cured or treatment completed, with no mention of an
alternative diagnosis.’’
Cost and Cost-Effectiveness
We estimated the unit cost of TB culture under two different
scenarios of laboratory throughput: observed throughput (eight
patients/week) and estimated maximum throughput using existing
equipment and staff (24 patients/week) (Table 1). The greatest
single cost was the weekly transportation of specimens and results
to each clinic. As throughput increased, culture tubes and reagents
accounted for an increasing proportion of TB culture costs,
particularly for MGIT. Table 2 presents other parameters used to
model the cost-effectiveness of TB culture. Assuming eight patients
per week, use of MGIT reduced staff time required for TB culture
(i.e., excluding smear, senior oversight, etc.) by 8% compared to
solid media (data not shown).
We estimated that, for every 1,000 HIV-positive TB suspects
presenting to clinics without access to TB culture, 188 would have
active TB, resulting in 73 secondary TB infections and 17 TB
Impact of TB Culture in Brazil
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TB would receive inappropriate TB therapy. Implementing TB
culture with solid media would avert 8 TB deaths (95% SI: 4, 15)
and 17 secondary infections (95% SI: 6, 36) but would trigger
inappropriate TB treatment of 44 additional patients (95% SI: 34,
57) with growth of NTM but not TB in culture. Replacing solid
media with MGIT would avert one further death (95% SI: 21, 4)
and five secondary infections (95% SI: -1, 12) but would generate
35 further inappropriate treatments (95% SI: 13, 59).
Compared with TB diagnosis using sputum smear alone, TB
culture with solid media was estimated to avert 37 DALYs (95%
SI: 13, 76) per 1,000 TB suspects, at a cost of $36 (95% SI: $25,
Table 1. Unit Cost Estimates for Expanded TB Culture Program (in 2006 US$).
Item/Category 8 Patients per Week 24 Patients per Week
Solid Media
a MGIT
b Solid Media
a MGIT
b
Variable Costs
Culture tubes and media $0.59 $3.00 $0.59 $3.00
Decontamination reagents $0.83 $0.83 $0.83 $0.83
Cryovials for pellet storage $0.00 $0.81 $0.00 $0.81
Lab supplies (e.g., pipette tips, centrifuge tubes) $0.53 $0.53 $0.53 $0.53
Fixed Costs
Transportation
c $9.61 $8.57 $3.20 $2.86
Automated MGIT 960 reader $0.00 $4.62 $0.00 $1.54
Laboratory personnel
c $4.21 $3.75 $1.40 $1.25
Lab supplies (e.g., mini-pipettes, vortex machine)
d $1.17 $1.00 $0.39 $0.33
Lab equipment (e.g., incubator, freezer)
d $0.59 $0.39 $0.20 $0.13
Total cost per Negative Culture $17.52 $23.50 $7.14 $11.28
Confirmation/speciation $7.90 $9.18 $7.82 $8.24
Total cost per Positive Culture $25.42 $32.68 $14.96 $19.52
MGIT, Mycobacteria Growth Indicator Tube.
aPrice per specimen, including five Lowenstein-Jensen slants (see Methods).
bPrice per culture tube: one per specimen, re-inoculated if contaminated (see Methods).
cDifferences between MGIT and solid media reflect higher volume of MGIT specimens (due to re-inoculation) at the same cost, thus reducing cost per MGIT specimen
relative to solid media.
dDifferences between MGIT and solid media partially reflect higher volume of MGIT specimens (due to re-inoculation) at the same cost.
doi:10.1371/journal.pone.0004057.t001
Figure 1. Patient Flow Diagram. In this diagram, ‘‘positive’’ denotes a positive result on any smear, slant, or tube, and ‘‘negative’’ denotes the
absence of such a result, including if all specimens are contaminated. ‘‘Treated’’ denotes treatment for TB, and ‘‘treated empirically’’ refers to treatment
initiated prior to the availability of culture results. HIV, human immunodeficiency virus; TB, tuberculosis; NTM, non-tuberculous mycobacteria.
doi:10.1371/journal.pone.0004057.g001
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Parameter Value (Sensitivity Range) Reference
Study Characteristics
Number of clinics served 29 (22–36) Study data
Number of TB suspects per week 8 (6–10) Study data
Number of specimens per diagnostic attempt 1.69 (1.27–2) Study data
Prevalence of TB among TB suspects
a 0.19 (0.14–0.24) Study data
TB Diagnosis: Baseline
Sensitivity of sputum smear 0.30 (0.23–0.38) Study data
Sensitivity of clinician diagnosis for smear-negative TB 0.56 (0.42–0.70) [12]
Specificity of clinician diagnosis (including smear) 0.91 (0.68–1.0) [29]
Days to repeat presentation if TB not diagnosed 113 (85–141) Study data
TB Diagnosis: Culture
b
Contamination rate per diagnostic attempt Study data
Solid media 0.09 (0.07–0.11)
MGIT 0.008
c (0.006–0.011)
Sensitivity per diagnostic attempt, smear-positive TB Study data
Solid media 1.0 (0.75–1.0)
MGIT 1.0 (0.75–1.0)
Sensitivity per diagnostic attempt, smear-negative TB
a Study data
Solid media 0.64 (0.48–0.80)
MGIT 0.68
c (0.51–0.85)
Proportion of TB-negative cultures growing NTM (12specificity for active TB)
a Study data
Solid media 0.06 (0.04–0.07)
MGIT 0.10 (0.07–0.12)
Days to first positive culture for smear-negative TB Study data
Solid media 38 (29–48)
MGIT 29 (22–36)
Days from positive culture to TB treatment, mean 46 (34–58) Study data
Proportion of NTM cultures triggering TB therapy 0.36 (0.27–0.45) Study data
Proportion of TB-positive cultures triggering TB therapy 0.65 (0.49–0.81) Study data
Additional Cost Estimates
Cost of repeated diagnostic attempt (excluding culture) $28 ($21–$35) [30]
Cost of treating a single case of active TB $516 ($387–$645) [12]
Mean fraction of TB treatment course completed by patients with NTM infection who are treated for TB 0.81 (0.61–1.0) Study data
Outcomes and Transmission
Mortality rate of undiagnosed TB, per month 0.05 (0.04–0.06) [19]
Life expectancy of patient diagnosed with TB, years 19.5 (14.6–24.4) THRio data
Disability weight, HIV 0.24 (0.18–0.30)
d [31]
Disability weight, active TB 0.27 (0.20–0.34) [31]
Quality of life decrement, treatment for TB 0.14 (0.10–0.17)
e Assumption
Secondary infections per smear-negative case, per year 2.9 (2.2–3.6) [32,33]
Proportion of secondary infections progressing rapidly to active TB 0.05 (0.04–0.06) [32,34]
TB mortality among secondary cases of active TB 0.13 (0.10–0.17) [12]
TB, tuberculosis; MGIT, Mycobacteria Growth Indicator Tube; NTM, non-tuberculous.
mycobacteria; HIV, human immunodeficiency virus.
aThe estimated number of true-positives includes all confirmed cases, plus a proportion of culture-negative cases, assuming a positive predictive value of 52% for
clinician diagnosis based on the prevalence of TB and estimated sensitivity and specificity of clinical diagnosis.
bSolid media=five Lowenstein-Jensen slants per specimen; MGIT=one BBLH culture tube per specimen, re-inoculated if initially contaminated (see Methods). Sensitivity
and specificity are calculated among diagnostic attempts in which at least one culture was not contaminated. Diagnostic attempts may include more than one culture
specimen.
cThe lower contamination rate and higher sensitivity for MGIT over solid media reflect the practice of re-processing contaminated MGIT specimens, whereas solid
cultures were inoculated in parallel and not re-processed.
dDisability weight of 0.136 for HIV infection without AIDS [31], +0.1 for the burden of antiretroviral therapy.
eAssumes that TB treatment (lasting six months) results in 50% as much disability as active TB.
doi:10.1371/journal.pone.0004057.t002
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averted (Table 3). Replacing solid media with MGIT was
estimated to avert an additional 8 DALYs (95% SI: 24, 23) per
1,000 TB suspects at a cost of $22 (95% SI: $8, $37) per suspect,
giving an expected incremental cost-effectiveness ratio of $2751/
DALY (95% SI: $680, dominated) compared to solid media.
Increasing laboratory throughput threefold reduced the incre-
mental cost, and thus also improved the incremental cost-
effectiveness, of TB culture by more than 50% ($15 vs. $36 per
TB suspect; $414 vs. $962 per DALY averted for solid media).
Sensitivity Analysis
Results of one-way sensitivity analysis (Figure 2) show that the
cost-effectiveness of expanded TB culture was more sensitive to the
characteristics of the existing TB diagnostic system than the
characteristics of culture itself. Decreasing the sensitivity of
clinician diagnosis for smear-negative TB in the absence of culture
from 70% to 42% improved the estimated incremental cost-
effectiveness of TB culture from $2199 to $484 per DALY averted.
Other conditions associated with a more favorable cost-effective-
ness ratio included a low discount rate, longer delay to re-
presentation by patients with undiagnosed active TB, high
prevalence of smear-negative TB among TB suspects, and high
rate of treatment based on positive cultures (Figure 2). When the
three variables to which the model was most sensitive were set to
values least favorable to TB culture, the incremental cost-
effectiveness of culture (solid media) was $12,146 per DALY
averted. The corresponding ‘‘best-case’’ cost-effectiveness ratio
was $225 per DALY averted.
Discussion
This operational evaluation of a centralized TB culture program
serving HIV-positive patients in urban Brazil suggests that TB culture
has substantial impact and reasonable cost-effectiveness when
deployed in this setting. In this setting, we estimated that TB culture
could avert an estimated 37 DALYs per 1,000 TB suspects and
prevent 49% of all TB deaths occurring after initial presentation, at a
cost of $962 per DALY averted (solid media). Upgrading from solid
to liquid media averted an estimated 21% more DALYs at a cost of
$2751/DALY. Rather than culture costs per se, the primary drivers
of cost-effectiveness included clinical practices (e.g., empiric TB
treatment), communications or patient follow-up (e.g., translating
culture results into treatment), and TB prevalence.
Our findings suggest that TB culture can be implemented with
reasonablecost-effectivenessinurban,middle-incomeLatinAmerica.
Although there is no universally-accepted threshold for considering
an intervention ‘‘cost-effective,’’ the Commission for Macroeconom-
ics and Health [21] has proposed that interventions whose cost per
DALY averted is less than gross domestic product (GDP) per capita
be defined as ‘‘very cost-effective.’’ By this criterion, TB culture
among HIV-positive adults in Brazil (2007 GDP per capita: $9700
[22]) is very cost-effective. Although few studies have evaluated the
cost-effectiveness of TB diagnosis in Latin America, other TB
interventions have been shown to have a more favorable cost-
effectiveness profile. For example, treatment of multidrug-resistant
(MDR) TB in Peru was estimated to cost US$248 (converted to 2006
currency)per DALYaverted [23]. Increasing throughput reduces the
cost of TB culture substantially (Table 3), but similar or greater gains
in cost-effectiveness could be achieved by targeting TB culture to
regions with high TB prevalence and poor existing diagnostic
sensitivity for smear-negative TB (Figure 2).
The overall impact of TB culture may be substantially greater
than estimated here, as TB culture offers many clinical benefits
beyond strict TB diagnosis. For example, we found that TB
culture may triple the yield of bacteriologically-confirmed TB and
avert 23% of TB transmission events occurring after the initial
clinic visit. Furthermore, culture, unlike AFB smear, can
discriminate NTM from TB and can identify drug resistant TB,
thereby facilitating identification of optimal therapeutic strategies
in individual patients. Finally, the number of TB suspects screened
on a per-clinic basis in this study was relatively low, partially owing
to gradual implementation and uptake; as clinics and clinicians
adjust their practices to incorporate TB culture, both volume and
cost-effectiveness are likely to improve.
Our results underscore the importance of translating culture
results into clinical practice. In this study, despite weekly hand-
delivery of all results to clinics, six of 17 patients (35%) with smear-
negative TB were not initiated on TB therapy within 180 days of
the clinic receiving a positive culture result. Four of these six
patients had no entries in their medical records during that time,
suggesting that failure to notify individual physicians and/or
patients of positive culture results, or failure/inability of patients to
report back to clinic, was responsible for the majority of such
missed treatment opportunities. These results demonstrate that TB
culture must be accompanied by effective post-laboratory
procedures including information transfer, clinician education
and training, and patient follow-up.
Table 3. Cost-Effectiveness of Expanded TB Culture per 1,000 TB Suspects.
Scenario Cost (61,000)
a
DALYs
Averted
Incremental Cost
(61,000)
a
Incremental DALYs
Averted
Incremental Cost-Effectiveness
Ratio
Throughput: 8 Patients/Week
Baseline $130 ($94, $173) 0 (ref) $0 (ref) 0 (ref) 0 (ref)
TB Culture: Solid Media $166 ($129, $209) 37 (13, 76) $36 ($25, $50) 37 (13, 76) $962/DALY ($469, $2642)
TB Culture: MGIT $188 ($147, $235) 45 (16, 91) $22 ($8, $37) 8 (24, 23) $2751/DALY ($680, dominated
b)
Throughput: 24 Patients/Week
Baseline $130 ($94, $173) 0 (ref) $0 (ref) 0 (ref) 0 (ref)
TB Culture: Solid Media $145 ($110, $189) 37 (13, 77) $15 ($10, $22) 37 (13, 77) $414/DALY ($198, $1141)
TB Culture: MGIT $161 ($123, $206) 45 (16, 94) $15 ($9, $22) 8 (24, 23) $1936/DALY ($600, dominated
b)
DALY, disability-adjusted life year; TB, tuberculosis; MGIT, Mycobacteria Growth Indicator Tube.
aCosts are reported in 2006 US$ and include all costs to the national tuberculosis program other than the baseline evaluation.
bHigher cost and lower effectiveness than the alternative, thus precluding calculation of a meaningful cost-effectiveness ratio.
doi:10.1371/journal.pone.0004057.t003
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effectiveness of TB culture as a whole; our small sample size
precludes an authoritative comparison of MGIT versus solid
media. Nevertheless, our results suggest that, if inoculated in
parallel from a single clinical specimen, culture in solid media can
achieve similar sensitivity to liquid media. In this analysis, five
Lowenstein-Jensen slants achieved equivalent sensitivity to one
MGIT tube. The additional benefit of MGIT over solid media
resulted from MGIT’s speed of diagnosis and the practice of re-
processing MGIT cultures if contaminated. Of the 8 incremental
DALYs averted by MGIT over solid media (Table 3), 4 were
attributable to faster time to diagnosis, and 4 to increased
sensitivity from re-processing of patient specimens.
TB culture resulted here in an unexpectedly high number of
specimens positive for non-tuberculous mycobacteria, especially
using MGIT. In fact, over 33% of positive cultures in TB suspects
with negative sputum smears were identified as NTM rather than
M. tuberculosis. Other studies have found increased NTM
prevalence in a variety of developed-country settings [24–26],
but the relevance of these findings to developing countries is
unclear, as the relative prevalence of M. tuberculosis is higher. The
present study highlights the importance of performing mycobac-
terial species identification in a developing-country setting and
suggests that rapid methods to distinguish TB from other
infections at the time of a positive culture result [27] may greatly
enhance appropriate clinical decision-making.
This study has a number of limitations. First, our sample size of
confirmed TB cases was small, and thus many of our parameter
estimates are imprecise. However, our sensitivity analysis (Figure 2)
suggests that the cost-effectiveness of TB culture is relatively
insensitive to TB culture’s accuracy or price; solid-media culture
with 50% sensitivity for smear-negative TB and a cost of $50 per
culture would still have an incremental cost-effectiveness of $1880
per DALY averted. Second, while our setting–a laboratory with
existing TB culture capacity serving HIV patients in urban Brazil–
is likely relevant to many middle-income regions in Latin America,
our findings may not generalize to those settings (e.g., sub-Saharan
Africa) where the co-epidemics of TB and HIV are most
devastating. Third, certain aspects of our diagnostic algorithm
may not be standard practice in other settings, making cost-
effectiveness estimates more difficult to translate to local
conditions. For example, we performed five parallel solid-media
cultures (two with inhibitors) for each specimen, reflecting
standard local lab practices in Rio de Janeiro. We also refrigerated
unprocessed specimens for up to one week before transport to the
laboratory. Both parallel processing and refrigeration would be
expected to impact the estimated sensitivity of TB culture; Figure 2
shows the expected effect on cost-effectiveness of a 25% variation
in this parameter. Finally, data for construction of the full cost-
effectiveness model were limited. Thus, we could not adopt a
societal perspective for our cost-effectiveness estimates, making our
results less comparable to those from other studies [28]. However,
the cost of TB culture to other members of society (e.g., patients) is
likely small, and as mentioned above, our cost-effectiveness
estimates may be conservative due to exclusion of ancillary
benefits of TB culture. Other relevant data limitations include
treatment outcomes, appropriate disability weights in HIV-
positive patients undergoing TB treatment, and the true TB status
of patients empirically treated for TB without a positive culture
result.
In conclusion, this study suggests that TB culture for HIV-
positive patients in urban Brazil may have substantial impact and
Figure 2. Results from One-Way Sensitivity Analysis. The effect of parameter variation on the estimated incremental cost-effectiveness ratio
(ICER) for tuberculosis (TB) culture on solid media is shown. Results are similar for MGIT (data not shown). All parameters are varied by 625% of their
initial value (Table 2) except for the discount rate, which is varied from 0% to 7%. Only those parameters for which such variation changed the
estimated ICER by 620% are shown. Costs are in 2006 US dollars.
doi:10.1371/journal.pone.0004057.g002
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to characteristics of the existing clinical infrastructure than to the
cost or accuracy of TB culture itself; to be effective, TB culture
must be implemented with programs to ensure effective commu-
nication between lab, clinic, and patient. Non-tuberculous
mycobacteria accounted for an unexpectedly large proportion
(.33%) of all positive culture isolates in this moderate TB
prevalence setting, further emphasizing the need for rapid species
identification methods to complement culture. TB culture is a
potentially effective and cost-effective tool for use among HIV-
positive patients in resource-constrained settings, but integration
with existing clinical systems and strengthening of post-analytical
processes are required to maximize impact.
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